Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

Affiliations

Comment

Helmut Oettle et al. Nat Clin Pract Oncol. 2007 Dec.

. 2007 Dec;4(12):686-7.

doi: 10.1038/ncponc0960.

¹ Charité School of Medicine, Department of Medical Oncology and Hematology, Campus Virchow-Klinikum, Berlin 13353, Germany. helmut.oettle@charite.de

No abstract available

Comment on

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Moore MJ, et al. J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452677 Clinical Trial.